Title	Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer
ID	3365602
External ID	7224710251
Author	Parag Mahanti
Published Date	Oct. 18, 2024, 6:28 a.m.
Summary	If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment
Tags	press-release
URL	https://smb.thecoastlandtimes.com/article/novartis-receives-positive-chmp-opinion-for-kisqalir-to-help-reduce-risk-of-recurrence-in-people-with-hrher2-early-breast-cancer?storyid=67123f5d6a8849190f525
Sentiment	Negative: 0.01563 Neutral: 0.54722 Positive: 0.43714
Relevance	0.00870

Content ID	1736319
Key	c730421a-694c-4ec1-83cb-f142ebd8fd53
Content	If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment with Kisqali ® (ribociclib) in combination with an aromatase inhibitor 1 Recommendation is based on the Phase III NATALEE trial, where Kisqali added to endocrine therapy (ET) significantly reduced the risk of recurrence by 25% versus ET alone across a broad population of patients with HR+/HER2- early breast cancer People with stage II or III HR+/HER2- EBC face significant risk of recurrence – often as incurable metastatic disease – despite adjuvant ET and regardless of nodal involvement ; at ESMO 2024, an updated analysis from NATALEE was presented, showing a deepening invasive disease-free survival benefit EAST HANOVER, N.J. /PRNewswire/ -- Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting marketing authorization for Kisqali ® (ribociclib) for the adjuvant treatment of adults with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (EBC), at high risk of disease recurrence, including those with node-negative disease 1. "One-third of people diagnosed with stage II breast cancer and more than half of those diagnosed with stage III will unfortunately experience a return of their cancer in the long term, often as metastatic disease," said Peter A. Fasching, M.D., Professor of Translational Medicine, University Hospital Erlangen and Comprehensive Cancer Center Erlangen-EMN and NATALEE trial investigator. "If approved, Kisqali could provide an effective and tolerable adjuvant treatment option to mitigate the risk of recurrence in a broader patient population, particularly for patients who currently have limited treatment options, including those with high-risk node-negative disease." Breast cancer is the most commonly diagnosed cancer in Europe 7. HR+/HER2- is the most common subtype, accounting for approximately 70% of all breast cancers, and more than 40% of these are diagnosed in stage II or III 8-10 2,11,12. In the trial, Kisqali plus endocrine therapy (ET), compared to ET alone, lowered the risk of cancer recurrence by 25.1% in patients with stage II and III HR+/HER2- EBC (HR=0.749; 95% CI: 0.628, 0.892; P =0.0006) and demonstrated a consistent, clinically meaningful invasive disease-free survival (iDFS) benefit across key pre-specified subgroups 2,11. Data from the pivotal trial also showed the safety profile of Kisqali at the 400mg dose was well-tolerated with generally low-grade symptomatic adverse events 2,11 An updated analysis from the NATALEE trial recently presented at the European Society for Medical Oncology (ESMO) Congress 2024 adds to the growing body of evidence supporting the potential of Kisqali to consistently reduce risk of recurrence across a broad population 6. In the updated analysis, the iDFS benefit continued to deepen beyond the three-year Kisqali treatment period in all patient subgroups, including those with node-negative disease 2. Europe lack options beyond endocrine therapy to help reduce their risk of cancer coming back. If approved, Kisqali could nearly double the number of patients eligible for CDK4/6 inhibitor adjuvant therapy,"said Patrick Horber M.D., President, International, Novartis."Together with the recent FDA approval and late-breaking NATALEE data presented at ESMO, today's positive CHMP recommendation further reinforces the differentiated profile of Kisqali as a new treatment option for a broad population of patients, including those with node-negative disease." Following the CHMP's recommendation to approve Kisqali in a broad population of patients diagnosed with HR+/HER2- EBC at high risk of recurrence, the European Commission (EC) will take a final decision within approximately two months. About NATALEE (ribociclib) with ET as an investigational adjuvant treatment versus ET alone in patients with stage II and III HR+/HER2- EBC, being conducted in collaboration with TRIO 2,13. The adjuvant ET in both treatment arms was a non-steroidal aromatase inhibitor (NSAI; anastrozole or letrozole) and goserelin if applicable 2,13. The primary endpoint of NATALEE is invasive disease-free survival (iDFS) as defined by the Standardized Definitions for Efficacy End Points (STEEP) criteria 2,13 2,13 About Kisqali ® (ribociclib) Kisqali ® (ribociclib) is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. Kisqali has been approved as a treatment for metastatic breast cancer (MBC) patients in 99 countries worldwide, including by the U.S. FDA and the European Commission 14,15. In the U.S., Kisqali is indicated for the treatment of adults with HR+/HER2- advanced or MBC in combination with an AI as initial ET or fulvestrant as initial ET or following disease progression on ET in post-menopausal women or in men 14. In the EU, Kisqali is approved for the treatment of women with HR+/HER2- advanced or MBC in combination with either an AI or fulvestrant as initial ET or following disease progression 15 14,15 for breast cancer recommend ribociclib (Kisqali) as the only Category 1 preferred CDK4/6 inhibitor for first-line treatment of people living with HR+/HER2- when combined with an AI, making Kisqali the preferred first-line treatment of choice for US prescribers in HR+/HER2- MBC 27. Additionally, Kisqali has the highest rating of any CDK4/6 inhibitor on the ESMO Magnitude of Clinical Benefit Scale, achieving a score of five out of five for first-line pre-menopausal patients with HR+/HER2- advanced breast cancer 28. Further, Kisqali in combination with either letrozole or fulvestrant has uniquely, among other CDK4/6 inhibitors, received a score of four out of five for post-menopausal patients with HR+/HER2- advanced breast cancer treated in the first line 29. Please see full Prescribing Information for Kisqali, available at About Novartis in Breast Cancer For more than 30 years, Novartis has been at the forefront of driving scientific advancements for people touched by breast cancer and improving clinical practice in collaboration with the global community. With one of the most comprehensive breast cancer portfolios and pipeline, Novartis leads the industry in discovery of new therapies and combinations in HR+/HER2- breast cancer, the most common form of the disease. Indication What is KISQALI? KISQALI ® (ribociclib) is a prescription medicine used to treat adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer: in combination with an aromatase inhibitor for stage II and III early breast cancer with a high risk of coming back that has gotten worse or has spread to other parts of the body (advanced or metastatic breast cancer) in combination with: It is not known if KISQALI is safe and effective in children. IMPORTANT SAFETY INFORMATION KISQALI may cause serious side effects, including: Lung problems. KISQALI may cause severe or life-threatening inflammation of the lungs during treatment that may lead to death. Tell your health care provider right away if you have any new or worsening symptoms, including: trouble breathing or shortness of breath cough with or without mucus chest pain Severe skin reactions. Tell your health care provider or get medical help right away if you get severe rash or rash that keeps getting worse; reddened skin; flu-like symptoms; skin pain or burning, blistering of the lips, eyes, or mouth, blisters on the skin or skin peeling, with or without fever. Your health care provider should check your heart and do blood tests before and during treatment with KISQALI Tell your health care provider right away if you have a change in your heartbeat (a fast or irregular heartbeat), or if you feel dizzy or faint Liver problems. KISQALI can cause serious liver problems. Your health care provider should do blood tests to check your liver before and during treatment with KISQALI. Tell your health care provider right away if you get any of the following signs and symptoms of liver problems: yellowing of your skin or the whites of your eyes (jaundice) dark or brown (tea-colored) urine feeling very tired loss of appetite pain on the upper right side of your stomach area (abdomen) bleeding or bruising more easily than normal Low white blood cell counts (neutropenia). Low white blood cell counts are very common during treatment with KISQALI and may result in infections that may be severe. Your health care provider should check your white blood cell counts before and during treatment with KISQALI. Tell your health care provider right away if you have signs and symptoms of low white blood cell counts or infections, such as fever and chills. Your health care provider may tell you to decrease your dose, temporarily stop, or completely stop taking KISQALI if you develop certain serious side effects during treatment with KISQALI. What should I tell my health care provider before taking KISQALI? Before you take KISQALI, tell your health care provider if you: have any heart problems, including heart failure, irregular heartbeats, and QT prolongation have ever had a heart attack have a slow heartbeat (bradycardia) have high blood pressure that is not controlled have decreased thyroid gland (hypothyroidism) have problems with the amount of potassium, calcium, phosphorus, or magnesium in your blood have fever, chills, or any other signs or symptoms of infection have liver problems have kidney problems are pregnant, or plan to become pregnant. KISQALI can harm your unborn baby are breastfeeding or plan to breastfeed. It is not known if KISQALI passes into your breast milk. Do not breastfeed during treatment with KISQALI and for at least 3 weeks after the last dose of KISQALI Tell your health care provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. KISQALI and other medicines may affect each other, causing side effects. Know the medicines you take. Keep a list of them to show your health care provider or pharmacist when you get a new medicine. What should I avoid while taking KISQALI? Avoid eating grapefruit and avoid drinking grapefruit juice during treatment with KISQALI since these may increase the amount of KISQALI in your blood. The most common side effects of KISQALI in people with early breast cancer include: decreased white blood cell counts decreased red blood cell counts increased liver function tests infections increased kidney function test decreased platelet counts nausea headache tiredness The most common side effects of KISQALI in people with advanced or metastatic breast cancer include: decreased white blood cell counts decreased red blood cell counts increased liver function tests infections nausea increased kidney function test tiredness decreased platelet counts diarrhea vomiting headache constipation hair loss cough rash back pain low blood sugar level KISQALI may cause fertility problems in males, which may affect your ability to father a child. Talk to your health care provider if this is a concern for you. These are not all the possible side effects of KISQALI. For more information, ask your health care provider or pharmacist. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit Please see accompanying full Disclaimer This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as "potential," "can," "will," "plan," "may," "could," "would," "expect," "anticipate," "look forward," "believe," "committed," "investigational," "pipeline," "launch," "to reduce," "remains," "continue," "transform," "evaluate," "likelihood," "ensuring," "updates," "should," or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for Kisqali in combination with an aromatase inhibitor (AI), or regarding potential future revenues from such product. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that Kisqali in combination with an AI will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that Kisqali in combination with an AI will be commercially successful in the future. In particular, our expectations regarding Kisqali in combination with an AI could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Reimagine medicine with us: Visit us at References European Medicines Agency (EMA). Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp14- 17-october-2024 Slamon D, Lipatov O, Nowecki Z, et al. Ribociclib plus Endocrine Therapy in Early Breast Cancer. N Engl J Med. 2024;390(12):1080-1091. doi:10.1056/NEJMoa2305488 Pan H, Gray R, Braybrooke J, et al. 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. N Engl J Med. 2017;377(19):1836-1846. doi:10.1056/NEJMoa1701830 Gomis RR, Gawrzak S. Tumor cell dormancy. Mol Oncol. 2017;11(1):62-78. doi:10.1016/j.molonc.2016.09.009 Novartis. Press release. FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer. September 17, 2024. Accessed October 15, 2024. https://www.novartis.com/news/media-releases/fda-approves-novartis-kisqali-reduce-risk-recurrence-people-hrher2-early-breast-cancer Fasching PA. Adjuvant Ribociclib (RIB) Plus Nonsteroidal Aromatase Inhibitor (NSAI) in Patients (Pts) With HR+/HER2− Early Breast Cancer (EBC): 4-Year Outcomes From the NATALEE Trial. LBA13. Proffered Paper presented at the European Society for Medical Oncology Congress (ESMO); September 16, 2024 ; Barcelona, Spain The Global Cancer Observatory. Cancer Today: GLOBOCAN 2022 Europe. 2024. Accessed October 15, 2024. https://gco.iarc.who.int/media/globocan/factsheets/populations/908-europe-fact-sheet.pdf American Cancer Society. Breast Cancer Facts & Figures 2019-2020. 2019. Accessed October 15. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/breast-cancer-facts-and-figures-2019-2020.pdf Howlader N, Altekruse SF, Li CI, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106(5):dju055. doi:10.1093/jnci/dju055 Criscitiello C, Spurden D, Piercy J, et al. Health-Related Quality of Life Among Patients With HR+/HER2- Early Breast Cancer. Clin Ther. 2021;43(7):1228-1244.e4. doi:10.1016/j.clinthera.2021.04.020 Hortobagyi G, Stroyakovskiy D, Yardley DA, et al. Ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2- early breast cancer: final invasive disease-free survival (iDFS) analysis from the NATALEE trial. Presented at San Antonio Breast Cancer Symposium (SABCS); December 8, 2023 ; San Antonio, Slamon D, Stroyakovskiy D, Yardley D, et al. Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2− early breast cancer: primary results from the Phase III NATALEE trial. Presented at the American Society of Clinical Oncology Annual Meeting (ASCO); June 2, 2023 ; Chicago, USA. Clinicaltrials.gov. NCT03701334. A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/ HER2- Early Breast Cancer (NATALEE). Updated October 10, 2024. Accessed Kisqali. US FDA. Prescribing Information. Novartis Pharmaceuticals Corporation; 2024. Updated September 2024. Accessed October 15, 2024. https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf Kisqali. EMA. Summary of product characteristics (SmPC). Novartis Europharm Limited; 2024. Updated August 21, 2024. Accessed October 15, 2024. https://www.ema.europa.eu/en/documents/product-information/kisqali-epar-product-information_en.pdf Yardley DA, et al. Pooled exploratory analysis of survival in patients (pts) with HR+/HER2- advanced breast cancer (ABC) and visceral metastases (mets) treated with ribociclib (RIB) + endocrine therapy (ET) in the MONALEESA (ML) trials. Poster presented at the European Society of Medical Oncology Congress (ESMO); September 9-13, 2022 ; Paris, France Neven P, et al. Updated overall survival (OS) results from the first-line (1L) population in the Phase III MONALEESA-3 trial of postmenopausal patients with HR+/HER2- advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL). Mini oral presented at the European Society for Medical Oncology Breast Cancer Congress; May 4, 2022 ; Paris, France Hortobagyi GN, Stemmer SM, Burris HA, et al. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. N Engl J Med. 2022;386(10):942-950. doi:10.1056/NEJMoa2114663 Hortobagyi GN, et al. Overall survival (OS) results from the phase III MONALEESA (ML)-2 trial of postmenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib. LBA 17. Proffered paper presented at the European Society of Medical Oncology Congress (ESMO); September 16-21, 2021 ; Lugano, Switzerland Im SA, Lu YS, Bardia A, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 2019;381(4):307-316. doi:10.1056/NEJMoa1903765 Slamon DJ, Neven P, Chia S, et al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. N Engl J Med. 2020;382(6):514-524. doi:10.1056/NEJMoa1911149 Slamon D, et al. Overall survival (OS) results of the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2-) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB). LBA7_PR. Presented at the European Society of Medical Oncology Congress (ESMO); September 29, 2019 ; Barcelona, Spain Slamon D, et al. Updated overall survival (OS) results from the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2− advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB). Presented at the American Society of Clinical Oncology Annual Meeting (ASCO); June 5, 2021 ; Chicago, USA Tripathy D, et al. Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- or perimenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib. Presented at the San Antonio Breast Cancer Symposium (SABCS); December 9, 2020 ; Texas, USA Yardley DA, et al. Overall survival (OS) in patients (pts) with advanced breast cancer (ABC) with visceral metastases (mets), including those with liver mets, treated with ribociclib (RIB) plus endocrine therapy (ET) in the MONALEESA (ML) -3 and -7 trials. Presented at the American Society of Clinical Oncology Annual Meeting (ASCO); May 29-31, 2020 ; O'Shaughnessy J, et al. Overall survival subgroup analysis by metastatic site from the Phase III MONALEESA-2 study of first-line ribociclib + letrozole in postmenopausal patients with HR+/HER2− advanced breast cancer. Presented at the San Antonio Breast Cancer Symposium (SABCS); December 7-10, 2021 ; Texas, USA NCCN Guidelines. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) – Breast Cancer Version 4.2024. Updated July 3, 2024. Accessed October 15, 2024. European Society for Medical Oncology. Magnitude of Clinical Benefit Scale Scorecard. Updated August 14, 2023. Accessed October 15, 2024. https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-158-1 European Society for Medical Oncology. Magnitude of Clinical Benefit Scale Scorecard. Updated April 25, 2024. Accessed October 15, 2025. https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-9-1 Novartis Media Relations North America Michael Meo Novartis Investor Relations North America Sloan Simpson Jonathan Graham Parag Mahanti https://www.prnewswire.com/news-releases/novartis-receives-positive-chmp-opinion-for-kisqali-to-help-reduce-risk-of-recurrence-in-people-with-hrher2--early-breast-cancer-302280311.html
Content Reference URL	None

Publisher Name	The Coastland Times (#946)
Publisher URL	https://smb.thecoastlandtimes.com
Description	None
Trust Flow Score	14
Citation Flow Score	34

Data Source Name	Quantexa News (#5)
Data Source Type	news
Data Source URL	https://app.aylien.com/dashboard
Description	Welcome to Quantexa News API — the most powerful way to aggregate, filter, and integrate global news data into your apps and models.
Weight	10

DJDT

Versions

Package	Name	Version
Django		5.2.1
Python		3.11.8
coverage	Coverage	7.4.4
debug_toolbar	Debug Toolbar	4.3.0
django_extensions	Django Extensions	5.2.1
grappelli	Grappelli	4.0.2

Time

Resource usage

Resource	Value
User CPU time	48.001 msec
System CPU time	0.350 msec
Total CPU time	48.351 msec
Elapsed time	77.896 msec
Context switches	13 voluntary, 1 involuntary

Browser timing

Timing attribute	Timeline	Milliseconds since navigation start (+length)

Settings from app.settings

Setting	Value
ABSOLUTE_URL_OVERRIDES	`{}`
ADMINS	`[]`
ALLOWED_HOSTS	`['*']`
APPEND_SLASH	`True`
AUTH0_CLIENT_ID	`'********************'`
AUTH0_CLIENT_SECRET	`'********************'`
AUTH0_DOMAIN	`'********************'`
AUTHENTICATION_BACKENDS	`'********************'`
AUTH_PASSWORD_VALIDATORS	`'********************'`
AUTH_USER_MODEL	`'********************'`
BASE_DIR	`PosixPath('/mnt/disks/pennyloupe_disk/pennyloupe')`
CACHES	`{'default': {'BACKEND': 'django.core.cache.backends.filebased.FileBasedCache', 'LOCATION': '/var/tmp/django_cache'}}`
CACHE_MIDDLEWARE_ALIAS	`'default'`
CACHE_MIDDLEWARE_KEY_PREFIX	`'********************'`
CACHE_MIDDLEWARE_SECONDS	`600`
CELERY_BROKER_URL	`'redis://localhost:6379'`
CELERY_RESULT_BACKEND	`'redis://localhost:6379'`
CSRF_COOKIE_AGE	`31449600`
CSRF_COOKIE_DOMAIN	`None`
CSRF_COOKIE_HTTPONLY	`False`
CSRF_COOKIE_NAME	`'csrftoken'`
CSRF_COOKIE_PATH	`'/'`
CSRF_COOKIE_SAMESITE	`'Lax'`
CSRF_COOKIE_SECURE	`False`
CSRF_FAILURE_VIEW	`'django.views.csrf.csrf_failure'`
CSRF_HEADER_NAME	`'HTTP_X_CSRFTOKEN'`
CSRF_TRUSTED_ORIGINS	`[]`
CSRF_USE_SESSIONS	`False`
DATABASES	`{'default': {'ATOMIC_REQUESTS': False, 'AUTOCOMMIT': True, 'CONN_HEALTH_CHECKS': False, 'CONN_MAX_AGE': 0, 'ENGINE': 'django.db.backends.postgresql', 'HOST': '34.125.28.12', 'NAME': 'pennyloupe', 'OPTIONS': {}, 'PASSWORD': '********************', 'PORT': '5432', 'TEST': {'CHARSET': None, 'COLLATION': None, 'MIGRATE': True, 'MIRROR': None, 'NAME': None}, 'TIME_ZONE': None, 'USER': 'pennyloupe'}}`
DATABASE_ROUTERS	`[]`
DATA_UPLOAD_MAX_MEMORY_SIZE	`2621440`
DATA_UPLOAD_MAX_NUMBER_FIELDS	`1000`
DATA_UPLOAD_MAX_NUMBER_FILES	`100`
DATETIME_FORMAT	`'N j, Y, P'`
DATETIME_INPUT_FORMATS	`['%Y-%m-%d %H:%M:%S', '%Y-%m-%d %H:%M:%S.%f', '%Y-%m-%d %H:%M', '%m/%d/%Y %H:%M:%S', '%m/%d/%Y %H:%M:%S.%f', '%m/%d/%Y %H:%M', '%m/%d/%y %H:%M:%S', '%m/%d/%y %H:%M:%S.%f', '%m/%d/%y %H:%M']`
DATE_FORMAT	`'N j, Y'`
DATE_INPUT_FORMATS	`['%Y-%m-%d', '%m/%d/%Y', '%m/%d/%y', '%b %d %Y', '%b %d, %Y', '%d %b %Y', '%d %b, %Y', '%B %d %Y', '%B %d, %Y', '%d %B %Y', '%d %B, %Y']`
DEBUG	`True`
DEBUG_PROPAGATE_EXCEPTIONS	`False`
DEBUG_TOOLBAR_CONFIG	`{'SHOW_TOOLBAR_CALLBACK': <function <lambda> at 0x7f3fcd3ef1a0>}`
DECIMAL_SEPARATOR	`'.'`
DEFAULT_AUTO_FIELD	`'django.db.models.BigAutoField'`
DEFAULT_CHARSET	`'utf-8'`
DEFAULT_EXCEPTION_REPORTER	`'django.views.debug.ExceptionReporter'`
DEFAULT_EXCEPTION_REPORTER_FILTER	`'django.views.debug.SafeExceptionReporterFilter'`
DEFAULT_FROM_EMAIL	`'webmaster@localhost'`
DEFAULT_INDEX_TABLESPACE	`''`
DEFAULT_TABLESPACE	`''`
DISALLOWED_USER_AGENTS	`[]`
EMAIL_BACKEND	`'django.core.mail.backends.smtp.EmailBackend'`
EMAIL_HOST	`'localhost'`
EMAIL_HOST_PASSWORD	`'********************'`
EMAIL_HOST_USER	`''`
EMAIL_PORT	`25`
EMAIL_SSL_CERTFILE	`None`
EMAIL_SSL_KEYFILE	`'********************'`
EMAIL_SUBJECT_PREFIX	`'[Django] '`
EMAIL_TIMEOUT	`None`
EMAIL_USE_LOCALTIME	`False`
EMAIL_USE_SSL	`False`
EMAIL_USE_TLS	`False`
FIELD_ENCRYPTION_KEY	`'********************'`
FILE_UPLOAD_DIRECTORY_PERMISSIONS	`None`
FILE_UPLOAD_HANDLERS	`['django.core.files.uploadhandler.MemoryFileUploadHandler', 'django.core.files.uploadhandler.TemporaryFileUploadHandler']`
FILE_UPLOAD_MAX_MEMORY_SIZE	`2621440`
FILE_UPLOAD_PERMISSIONS	`420`
FILE_UPLOAD_TEMP_DIR	`None`
FIRST_DAY_OF_WEEK	`0`
FIXTURE_DIRS	`[]`
FORCE_SCRIPT_NAME	`None`
FORMAT_MODULE_PATH	`None`
FORMS_URLFIELD_ASSUME_HTTPS	`False`
FORM_RENDERER	`'django.forms.renderers.DjangoTemplates'`
GCP_LOCATION	`'us-central1'`
GCP_PROJECT_ID	`'advance-honor-411011'`
GCP_PROJECT_NUMBER	`'268856636042'`
GCP_SERVICE_ACCOUNT	`'/Users/kcallahan/.config/gcloud/vector-search-user.json'`
GCP_VERTEX_BUCKET	`'pennyloupe-us-central1'`
GCP_VERTEX_INDEX_ID	`'2477861603379249152'`
GRAPPELLI_ADMIN_TITLE	`'Penny Loupe'`
GRAPPELLI_AUTOCOMPLETE_SEARCH_FIELDS	`{'auth': '********************'}`
IGNORABLE_404_URLS	`[]`
INSTALLED_APPS	`['coverage', 'grappelli', 'django.contrib.admin', 'django.contrib.auth', 'django.contrib.contenttypes', 'django.contrib.humanize', 'django.contrib.messages', 'django.contrib.postgres', 'django.contrib.sessions', 'django.contrib.staticfiles', 'django_htmx', 'app.core.apps.CoreConfig', 'django_extensions', 'debug_toolbar']`
INTERNAL_IPS	`['127.0.0.1']`
LANGUAGES	`[('en', 'English')]`
LANGUAGES_BIDI	`['he', 'ar', 'ar-dz', 'ckb', 'fa', 'ug', 'ur']`
LANGUAGE_CODE	`'en-us'`
LANGUAGE_COOKIE_AGE	`None`
LANGUAGE_COOKIE_DOMAIN	`None`
LANGUAGE_COOKIE_HTTPONLY	`False`
LANGUAGE_COOKIE_NAME	`'django_language'`
LANGUAGE_COOKIE_PATH	`'/'`
LANGUAGE_COOKIE_SAMESITE	`None`
LANGUAGE_COOKIE_SECURE	`False`
LOCALE_PATHS	`[]`
LOGGING	`{}`
LOGGING_CONFIG	`'logging.config.dictConfig'`
LOGIN_REDIRECT_URL	`'/accounts/profile/'`
LOGIN_URL	`'/accounts/login/'`
LOGOUT_REDIRECT_URL	`None`
MANAGERS	`[]`
MEDIA_ROOT	`PosixPath('/mnt/disks/pennyloupe_disk/pennyloupe/media')`
MEDIA_URL	`'/media/'`
MESSAGE_STORAGE	`'django.contrib.messages.storage.fallback.FallbackStorage'`
MIDDLEWARE	['django.middleware.security.SecurityMiddleware', 'whitenoise.middleware.WhiteNoiseMiddleware', 'django.contrib.sessions.middleware.SessionMiddleware', 'django.middleware.cache.UpdateCacheMiddleware', 'django.middleware.common.CommonMiddleware', 'django.middleware.csrf.CsrfViewMiddleware', 'django.contrib.auth.middleware.AuthenticationMiddleware', 'django.contrib.messages.middleware.MessageMiddleware', 'django.middleware.clickjacking.XFrameOptionsMiddleware', 'django_htmx.middleware.HtmxMiddleware', 'debug_toolbar.middleware.DebugToolbarMiddleware']
MIGRATION_MODULES	`{}`
MONTH_DAY_FORMAT	`'F j'`
NUMBER_GROUPING	`0`
OPENAI_API_KEY	`'********************'`
PASSWORD_HASHERS	`'********************'`
PASSWORD_RESET_TIMEOUT	`'********************'`
POLYGON_API_KEY	`'********************'`
PREPEND_WWW	`False`
QT_API_KEY	`'********************'`
QT_APP_ID	`'13d3cbab'`
QT_PASSWORD	`'********************'`
QT_USERNAME	`'kevin+dev3@pennyloupe.com'`
ROOT_URLCONF	`'app.urls'`
SALT_KEY	`'********************'`
SCRAPER_API_KEY	`'********************'`
SECRET_KEY	`'********************'`
SECRET_KEY_FALLBACKS	`'********************'`
SECURE_CONTENT_TYPE_NOSNIFF	`True`
SECURE_CROSS_ORIGIN_OPENER_POLICY	`'same-origin'`
SECURE_HSTS_INCLUDE_SUBDOMAINS	`False`
SECURE_HSTS_PRELOAD	`False`
SECURE_HSTS_SECONDS	`0`
SECURE_PROXY_SSL_HEADER	`None`
SECURE_REDIRECT_EXEMPT	`[]`
SECURE_REFERRER_POLICY	`'same-origin'`
SECURE_SSL_HOST	`None`
SECURE_SSL_REDIRECT	`False`
SERVER_EMAIL	`'root@localhost'`
SESSION_CACHE_ALIAS	`'default'`
SESSION_COOKIE_AGE	`1209600`
SESSION_COOKIE_DOMAIN	`None`
SESSION_COOKIE_HTTPONLY	`True`
SESSION_COOKIE_NAME	`'sessionid'`
SESSION_COOKIE_PATH	`'/'`
SESSION_COOKIE_SAMESITE	`'Lax'`
SESSION_COOKIE_SECURE	`False`
SESSION_ENGINE	`'django.contrib.sessions.backends.db'`
SESSION_EXPIRE_AT_BROWSER_CLOSE	`False`
SESSION_FILE_PATH	`None`
SESSION_SAVE_EVERY_REQUEST	`False`
SESSION_SERIALIZER	`'django.contrib.sessions.serializers.JSONSerializer'`
SETTINGS_MODULE	`'app.settings'`
SHORT_DATETIME_FORMAT	`'m/d/Y P'`
SHORT_DATE_FORMAT	`'m/d/Y'`
SIGNING_BACKEND	`'django.core.signing.TimestampSigner'`
SILENCED_SYSTEM_CHECKS	`[]`
SQL_FILES_DIR	`'/mnt/disks/pennyloupe_disk/pennyloupe/app/core/sql'`
STATICFILES_DIRS	`[]`
STATICFILES_FINDERS	`['django.contrib.staticfiles.finders.FileSystemFinder', 'django.contrib.staticfiles.finders.AppDirectoriesFinder']`
STATIC_ROOT	`PosixPath('/mnt/disks/pennyloupe_disk/pennyloupe/static')`
STATIC_URL	`'/static/'`
STORAGES	`{'default': {'BACKEND': 'django.core.files.storage.FileSystemStorage'}, 'staticfiles': {'BACKEND': 'django.contrib.staticfiles.storage.StaticFilesStorage'}}`
TEMPLATES	`[{'APP_DIRS': True, 'BACKEND': 'django.template.backends.django.DjangoTemplates', 'DIRS': ['templates'], 'OPTIONS': {'context_processors': ['django.template.context_processors.debug', 'django.template.context_processors.request', 'django.contrib.auth.context_processors.auth', 'django.contrib.messages.context_processors.messages']}}]`
TEST_NON_SERIALIZED_APPS	`[]`
TEST_RUNNER	`'django.test.runner.DiscoverRunner'`
THOUSAND_SEPARATOR	`','`
TIME_FORMAT	`'P'`
TIME_INPUT_FORMATS	`['%H:%M:%S', '%H:%M:%S.%f', '%H:%M']`
TIME_ZONE	`'UTC'`
USE_I18N	`True`
USE_THOUSAND_SEPARATOR	`False`
USE_TZ	`True`
USE_X_FORWARDED_HOST	`False`
USE_X_FORWARDED_PORT	`False`
WSGI_APPLICATION	`'app.wsgi.application'`
X_FRAME_OPTIONS	`'DENY'`
YEAR_MONTH_FORMAT	`'F Y'`

Headers

Request headers

Key	Value
Accept	/
Accept-Encoding	gzip, br, zstd, deflate
Host	pennyloupe.com
User-Agent	Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)

Response headers

Key	Value
Content-Type	text/html; charset=utf-8

WSGI environ

Since the WSGI environ inherits the environment of the server, only a significant subset is shown below.

Key	Value
CONTENT_LENGTH
CONTENT_TYPE
PATH_INFO	/ticker/III/content/3365602
QUERY_STRING
REMOTE_ADDR	216.73.216.158
REQUEST_METHOD	GET
SCRIPT_NAME
SERVER_NAME	pennyloupe.com
SERVER_PORT	443
SERVER_PROTOCOL	HTTP/1.1

Request

View information

View function	Arguments	Keyword arguments	URL name
`app.core.views.app.ticker_content_detail`	`()`	`{'content_id': 3365602, 'ticker': 'III'}`	`ticker_content_detail`

No cookies

No session data

No GET data

No POST data

SQL queries from 1 connection

default 16.34 ms (5 queries )

Query Timeline Time (ms) Action

SELECT "pl_content"."created_dt",
       "pl_content"."updated_dt",
       "pl_content"."status_id",
       "pl_content"."id",
       "pl_content"."key",
       "pl_content"."fetch_ref_id",
       "pl_content"."ticker",
       "pl_content"."publish_dt",
       "pl_content"."external_id",
       "pl_content"."published_by",
       "pl_content"."title",
       "pl_content"."summary",
       "pl_content"."tags",
       "pl_content"."url",
       "pl_content"."author",
       "pl_content"."author_reputation_score",
       "pl_content"."content_length",
       "pl_content"."parent_key",
       "pl_content"."sentiment_positive",
       "pl_content"."sentiment_negative",
       "pl_content"."sentiment_neutral",
       "pl_content"."sentiment",
       "pl_content"."sentiment_status",
       "pl_content"."relevance_score",
       "pl_content"."votes_positive",
       "pl_content"."votes_negative",
       "pl_content"."is_processing_flag",
       "pl_content"."vector_embedding_dt",
       "pl_content"."vector_id",
       "pl_content"."vector_status",
       "pl_content"."data_source_id",
       "pl_content"."parent_content_id",
       "pl_content"."publisher_id"
  FROM "pl_content"
WHERE "pl_content"."id" = 3365602
LIMIT 21SELECT ••• FROM "pl_content" WHERE "pl_content"."id" = 3365602 LIMIT 21

6.30

Connection: default

Transaction status: Idle

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/whitenoise/middleware.py in __call__(124)
  return self.get_response(request)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django_htmx/middleware.py in __call__(43)
  return self.get_response(request)

/mnt/disks/pennyloupe_disk/pennyloupe/app/core/views/app.py in ticker_content_detail(2297)
  content = Content.objects.get(id=content_id)

SELECT "pl_content_content"."created_dt",
       "pl_content_content"."updated_dt",
       "pl_content_content"."status_id",
       "pl_content_content"."id",
       "pl_content_content"."key",
       "pl_content_content"."content",
       "pl_content_content"."content_ref_url",
       "pl_content_content"."content_id"
  FROM "pl_content_content"
WHERE "pl_content_content"."content_id" = 3365602
ORDER BY "pl_content_content"."id" ASC
LIMIT 1SELECT ••• FROM "pl_content_content" WHERE "pl_content_content"."content_id" = 3365602 ORDER BY "pl_content_content"."id" ASC LIMIT 1

5.99

Connection: default

Transaction status: Idle

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/whitenoise/middleware.py in __call__(124)
  return self.get_response(request)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django_htmx/middleware.py in __call__(43)
  return self.get_response(request)

/mnt/disks/pennyloupe_disk/pennyloupe/app/core/views/app.py in ticker_content_detail(2303)
  content_content = ContentContent.objects.filter(details=content).first()

SELECT "pl_content_publisher"."created_dt",
       "pl_content_publisher"."updated_dt",
       "pl_content_publisher"."status_id",
       "pl_content_publisher"."id",
       "pl_content_publisher"."name",
       "pl_content_publisher"."url",
       "pl_content_publisher"."domain",
       "pl_content_publisher"."description",
       "pl_content_publisher"."weight",
       "pl_content_publisher"."trust_flow_score",
       "pl_content_publisher"."citation_flow_score"
  FROM "pl_content_publisher"
WHERE "pl_content_publisher"."id" = 946
LIMIT 21SELECT ••• FROM "pl_content_publisher" WHERE "pl_content_publisher"."id" = 946 LIMIT 21

1.47

Connection: default

Transaction status: Idle

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/whitenoise/middleware.py in __call__(124)
  return self.get_response(request)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django_htmx/middleware.py in __call__(43)
  return self.get_response(request)

/mnt/disks/pennyloupe_disk/pennyloupe/app/core/views/app.py in ticker_content_detail(2306)
  publisher = content.publisher

SELECT "pl_data_source"."created_dt",
       "pl_data_source"."updated_dt",
       "pl_data_source"."status_id",
       "pl_data_source"."id",
       "pl_data_source"."name",
       "pl_data_source"."type",
       "pl_data_source"."url",
       "pl_data_source"."description",
       "pl_data_source"."weight",
       "pl_data_source"."class_name",
       "pl_data_source"."class_params_json"
  FROM "pl_data_source"
WHERE "pl_data_source"."id" = 5
LIMIT 21SELECT ••• FROM "pl_data_source" WHERE "pl_data_source"."id" = 5 LIMIT 21

1.10

Connection: default

Transaction status: Idle

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/whitenoise/middleware.py in __call__(124)
  return self.get_response(request)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django_htmx/middleware.py in __call__(43)
  return self.get_response(request)

/mnt/disks/pennyloupe_disk/pennyloupe/app/core/views/app.py in ticker_content_detail(2307)
  data_source = content.data_source

SELECT COUNT(*) AS "__count"
FROM "pl_content"
WHERE "pl_content"."parent_content_id" = 3365602SELECT COUNT(*) AS "__count" FROM "pl_content" WHERE "pl_content"."parent_content_id" = 3365602

1.48

Connection: default

Transaction status: Idle

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/whitenoise/middleware.py in __call__(124)
  return self.get_response(request)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django_htmx/middleware.py in __call__(43)
  return self.get_response(request)

/mnt/disks/pennyloupe_disk/pennyloupe/app/core/views/app.py in ticker_content_detail(2319)
  return render(request, "ticker_content_detail.html", context)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/shortcuts.py in render(25)
  content = loader.render_to_string(template_name, context, request, using=using)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/loader.py in render_to_string(62)
  return template.render(context, request)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/backends/django.py in render(107)
  return self.template.render(context)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/base.py in render(171)
  return self._render(context)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/test/utils.py in instrumented_test_render(114)
  return self.nodelist.render(context)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/base.py in render(1016)
  return SafeString("".join([node.render_annotated(context) for node in self]))

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/base.py in <listcomp>(1016)
  return SafeString("".join([node.render_annotated(context) for node in self]))

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/base.py in render_annotated(977)
  return self.render(context)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/loader_tags.py in render(159)
  return compiled_parent._render(context)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/test/utils.py in instrumented_test_render(114)
  return self.nodelist.render(context)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/base.py in render(1016)
  return SafeString("".join([node.render_annotated(context) for node in self]))

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/base.py in <listcomp>(1016)
  return SafeString("".join([node.render_annotated(context) for node in self]))

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/base.py in render_annotated(977)
  return self.render(context)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/loader_tags.py in render(65)
  result = block.nodelist.render(context)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/base.py in render(1016)
  return SafeString("".join([node.render_annotated(context) for node in self]))

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/base.py in <listcomp>(1016)
  return SafeString("".join([node.render_annotated(context) for node in self]))

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/base.py in render_annotated(977)
  return self.render(context)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/defaulttags.py in render(320)
  match = condition.eval(context)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/smartif.py in eval(61)
  return func(context, self.first, self.second)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/smartif.py in <lambda>(107)
  ">": infix(10, lambda context, x, y: x.eval(context) > y.eval(context)),

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/defaulttags.py in eval(886)
  return self.value.resolve(context, ignore_failures=True)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/base.py in resolve(722)
  obj = self.var.resolve(context)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/base.py in resolve(854)
  value = self._resolve_lookup(context)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/base.py in _resolve_lookup(925)
  current = current()

27	`<td><a href="{% url 'ticker_content_detail' ticker=ticker content_id=content_detail.content.parent.id %}">{{ content_detail.content.parent.title }}</a></td>`
28	`</tr>`
29	`{% endif %}`
30	`{% if content_detail.content.children.count > 0 %}`
31	`<tr>`
32	`<th>Children</th>`
33	`<td>`
34	`<ul>`

/mnt/disks/pennyloupe_disk/pennyloupe/app/core/templates/ticker_content_detail.html

Static files (720 found, 2 used)

Static file paths

None

Static file apps

grappelli
django.contrib.admin
django_htmx
app.core
django_extensions
debug_toolbar

Static files

css/pennyloupe.css: /mnt/disks/pennyloupe_disk/pennyloupe/app/core/static/css/pennyloupe.css
img/penny_loupe_logo.png: /mnt/disks/pennyloupe_disk/pennyloupe/app/core/static/img/penny_loupe_logo.png

django.contrib.staticfiles.finders.AppDirectoriesFinder (720 files)

Templates (6 rendered)

Template path

templates

Templates

ticker_content_detail.html: /mnt/disks/pennyloupe_disk/pennyloupe/app/core/templates/ticker_content_detail.html; Toggle context
{'False': False, 'None': None, 'True': True} {'DEFAULT_MESSAGE_LEVELS': {'DEBUG': 10, 'ERROR': 40, 'INFO': 20, 'SUCCESS': 25, 'WARNING': 30}, 'csrf_token': '<SimpleLazyObject: <function csrf.<locals>._get_val at ' '0x7f3fb52e18a0>>', 'messages': <FallbackStorage: request=<WSGIRequest: GET '/ticker/III/content/3365602'>>, 'perms': PermWrapper(<SimpleLazyObject: <function AuthenticationMiddleware.process_request.<locals>.<lambda> at 0x7f3fb55a2700>>), 'request': '<<request>>', 'user': '<SimpleLazyObject: <function ' 'AuthenticationMiddleware.process_request.<locals>.<lambda> at ' '0x7f3fb55a2700>>'} {'content_detail': {'content': <Content: Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer - Parag Mahanti>, 'content_content': <ContentContent: Content ID: 1736319>, 'data_source': <DataSource: Quantexa News>, 'publisher': <ContentPublisher: The Coastland Times>}, 'ticker': 'III'}
base.html: /mnt/disks/pennyloupe_disk/pennyloupe/templates/base.html; Toggle context
{'False': False, 'None': None, 'True': True} {'DEFAULT_MESSAGE_LEVELS': {'DEBUG': 10, 'ERROR': 40, 'INFO': 20, 'SUCCESS': 25, 'WARNING': 30}, 'csrf_token': '<SimpleLazyObject: <function csrf.<locals>._get_val at ' '0x7f3fb52e18a0>>', 'messages': <FallbackStorage: request=<WSGIRequest: GET '/ticker/III/content/3365602'>>, 'perms': PermWrapper(<SimpleLazyObject: <function AuthenticationMiddleware.process_request.<locals>.<lambda> at 0x7f3fb55a2700>>), 'request': '<<request>>', 'user': '<SimpleLazyObject: <function ' 'AuthenticationMiddleware.process_request.<locals>.<lambda> at ' '0x7f3fb55a2700>>'} {'content_detail': {'content': <Content: Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer - Parag Mahanti>, 'content_content': <ContentContent: Content ID: 1736319>, 'data_source': <DataSource: Quantexa News>, 'publisher': <ContentPublisher: The Coastland Times>}, 'ticker': 'III'}
components/leftnav.html: /mnt/disks/pennyloupe_disk/pennyloupe/templates/components/leftnav.html; Toggle context
{'False': False, 'None': None, 'True': True} {'DEFAULT_MESSAGE_LEVELS': {'DEBUG': 10, 'ERROR': 40, 'INFO': 20, 'SUCCESS': 25, 'WARNING': 30}, 'csrf_token': '<SimpleLazyObject: <function csrf.<locals>._get_val at ' '0x7f3fb52e18a0>>', 'messages': <FallbackStorage: request=<WSGIRequest: GET '/ticker/III/content/3365602'>>, 'perms': PermWrapper(<SimpleLazyObject: <function AuthenticationMiddleware.process_request.<locals>.<lambda> at 0x7f3fb55a2700>>), 'request': '<<request>>', 'user': '<SimpleLazyObject: <function ' 'AuthenticationMiddleware.process_request.<locals>.<lambda> at ' '0x7f3fb55a2700>>'} {'content_detail': {'content': <Content: Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer - Parag Mahanti>, 'content_content': <ContentContent: Content ID: 1736319>, 'data_source': <DataSource: Quantexa News>, 'publisher': <ContentPublisher: The Coastland Times>}, 'ticker': 'III'} {'block': <Block Node: leftnav. Contents: [<TextNode: '\n <div'>, <IncludeNode: template=<FilterExpression '"components/leftnav.html"'>>, <TextNode: '\n </di'>]>}
components/header.html: /mnt/disks/pennyloupe_disk/pennyloupe/templates/components/header.html; Toggle context
{'False': False, 'None': None, 'True': True} {'DEFAULT_MESSAGE_LEVELS': {'DEBUG': 10, 'ERROR': 40, 'INFO': 20, 'SUCCESS': 25, 'WARNING': 30}, 'csrf_token': '<SimpleLazyObject: <function csrf.<locals>._get_val at ' '0x7f3fb52e18a0>>', 'messages': <FallbackStorage: request=<WSGIRequest: GET '/ticker/III/content/3365602'>>, 'perms': PermWrapper(<SimpleLazyObject: <function AuthenticationMiddleware.process_request.<locals>.<lambda> at 0x7f3fb55a2700>>), 'request': '<<request>>', 'user': '<SimpleLazyObject: <function ' 'AuthenticationMiddleware.process_request.<locals>.<lambda> at ' '0x7f3fb55a2700>>'} {'content_detail': {'content': <Content: Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer - Parag Mahanti>, 'content_content': <ContentContent: Content ID: 1736319>, 'data_source': <DataSource: Quantexa News>, 'publisher': <ContentPublisher: The Coastland Times>}, 'ticker': 'III'} {'block': <Block Node: header. Contents: [<TextNode: '\n\n '>, <IncludeNode: template=<FilterExpression '"components/header.html"'>>, <TextNode: '\n\n '>]>}
components/ticker_subnav.html: /mnt/disks/pennyloupe_disk/pennyloupe/app/core/templates/components/ticker_subnav.html; Toggle context
{'False': False, 'None': None, 'True': True} {'DEFAULT_MESSAGE_LEVELS': {'DEBUG': 10, 'ERROR': 40, 'INFO': 20, 'SUCCESS': 25, 'WARNING': 30}, 'csrf_token': '<SimpleLazyObject: <function csrf.<locals>._get_val at ' '0x7f3fb52e18a0>>', 'messages': <FallbackStorage: request=<WSGIRequest: GET '/ticker/III/content/3365602'>>, 'perms': PermWrapper(<SimpleLazyObject: <function AuthenticationMiddleware.process_request.<locals>.<lambda> at 0x7f3fb55a2700>>), 'request': '<<request>>', 'user': '<SimpleLazyObject: <function ' 'AuthenticationMiddleware.process_request.<locals>.<lambda> at ' '0x7f3fb55a2700>>'} {'content_detail': {'content': <Content: Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer - Parag Mahanti>, 'content_content': <ContentContent: Content ID: 1736319>, 'data_source': <DataSource: Quantexa News>, 'publisher': <ContentPublisher: The Coastland Times>}, 'ticker': 'III'} {'block': <Block Node: content. Contents: [<TextNode: '\n\n <div class="uk-flex'>, <IncludeNode: template=<FilterExpression '"components/ticker_subnav.html"'>>, <TextNode: '\n <!-- /SUB NAV--'>, <Variable Node: content_detail.content.title>, <TextNode: '</td>\n '>, <IfNode>, <TextNode: '\n '>, <IfNode>, <TextNode: '\n '>, <Variable Node: content_detail.content.id>, <TextNode: '</td>\n '>, <Variable Node: content_detail.content.external_id>, <TextNode: '</td>\n '>, <Variable Node: content_detail.content.author>, <TextNode: '</td>\n '>, <Variable Node: content_detail.content.publish_dt>, <TextNode: '</td>\n '>, <Variable Node: content_detail.content.summary>, <TextNode: '</td>\n '>, <Variable Node: content_detail.content.tags>, <TextNode: '</td>\n '>, <IfNode>, <TextNode: '\n '>, <Variable Node: content_detail.content.sentiment_negative>, <TextNode: '   \n '>, <Variable Node: content_detail.content.sentiment_neutral>, <TextNode: '   \n '>, <Variable Node: content_detail.content.sentiment_positive>, <TextNode: '<br/>\n '>, <django.template.defaulttags.WidthRatioNode object at 0x7f3fb6200ad0>, <TextNode: '%;"></div>\n '>, <Variable Node: content_detail.content.sentiment_neutral>, <TextNode: '" style="width:'>, <django.template.defaulttags.WidthRatioNode object at 0x7f3fb6340fd0>, <TextNode: '%;"></div>\n '>, <Variable Node: content_detail.content.sentiment_positive>, <TextNode: '" style="width:'>, <django.template.defaulttags.WidthRatioNode object at 0x7f3fb62011d0>, <TextNode: '%;"></div>\n '>, <Variable Node: content_detail.content.relevance_score>, <TextNode: '</td>\n '>, <IfNode>, <TextNode: '\n '>, <IfNode>, <TextNode: '\n <li clas'>, <Variable Node: content_detail.data_source.name>, <TextNode: '\n '>, <Variable Node: content_detail.data_source.id>, <TextNode: ')\n '>, <Variable Node: content_detail.data_source.type>, <TextNode: '</td>\n '>, <Variable Node: content_detail.data_source.url>, <TextNode: '" target="_blank">'>, <Variable Node: content_detail.data_source.url>, <TextNode: '</a></td>\n '>, <Variable Node: content_detail.data_source.description>, <TextNode: '</td>\n '>, <Variable Node: content_detail.data_source.weight>, <TextNode: '</td>\n '>]>} {'ticker': 'III'}
components/footer.html: /mnt/disks/pennyloupe_disk/pennyloupe/templates/components/footer.html; Toggle context
{'False': False, 'None': None, 'True': True} {'DEFAULT_MESSAGE_LEVELS': {'DEBUG': 10, 'ERROR': 40, 'INFO': 20, 'SUCCESS': 25, 'WARNING': 30}, 'csrf_token': '<SimpleLazyObject: <function csrf.<locals>._get_val at ' '0x7f3fb52e18a0>>', 'messages': <FallbackStorage: request=<WSGIRequest: GET '/ticker/III/content/3365602'>>, 'perms': PermWrapper(<SimpleLazyObject: <function AuthenticationMiddleware.process_request.<locals>.<lambda> at 0x7f3fb55a2700>>), 'request': '<<request>>', 'user': '<SimpleLazyObject: <function ' 'AuthenticationMiddleware.process_request.<locals>.<lambda> at ' '0x7f3fb55a2700>>'} {'content_detail': {'content': <Content: Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer - Parag Mahanti>, 'content_content': <ContentContent: Content ID: 1736319>, 'data_source': <DataSource: Quantexa News>, 'publisher': <ContentPublisher: The Coastland Times>}, 'ticker': 'III'} {'block': <Block Node: footer. Contents: [<TextNode: '\n '>, <IncludeNode: template=<FilterExpression '"components/footer.html"'>>, <TextNode: '\n '>]>}

Context processors

django.template.context_processors.csrf: Toggle context
{'csrf_token': <SimpleLazyObject: <function csrf.<locals>._get_val at 0x7f3fb52e18a0>>}
django.template.context_processors.debug: Toggle context
{}
django.template.context_processors.request: Toggle context
{'request': <WSGIRequest: GET '/ticker/III/content/3365602'>}
django.contrib.auth.context_processors.auth: Toggle context
{'user': <SimpleLazyObject: <function AuthenticationMiddleware.process_request.<locals>.<lambda> at 0x7f3fb55a2700>>, 'perms': PermWrapper(<SimpleLazyObject: <function AuthenticationMiddleware.process_request.<locals>.<lambda> at 0x7f3fb55a2700>>)}
django.contrib.messages.context_processors.messages: Toggle context
{'messages': <FallbackStorage: request=<WSGIRequest: GET '/ticker/III/content/3365602'>>, 'DEFAULT_MESSAGE_LEVELS': {'DEBUG': 10, 'INFO': 20, 'SUCCESS': 25, 'WARNING': 30, 'ERROR': 40}}

Cache calls from 1 backend

Summary

Total calls	Total time	Cache hits	Cache misses
0	0 ms	0	0

Commands

add	get	set	get_or_set	touch	delete	clear	get_many	set_many	delete_many	has_key	incr	decr	incr_version	decr_version
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Signals

Signal	Receivers
class_prepared
connection_created	register_type_handlers
got_request_exception
m2m_changed
post_delete
post_init
post_migrate	create_permissions, create_contenttypes
post_save	create_initial_trade_position
pre_delete
pre_init
pre_migrate	inject_rename_contenttypes_operations
pre_save
request_finished	close_old_connections, close_caches, reset_urlconf
request_started	reset_queries, close_old_connections
setting_changed	reset_cache, clear_cache_handlers, update_installed_apps, update_connections_time_zone, clear_routers_cache, reset_template_engines, storages_changed, clear_serializers_cache, language_changed, localize_settings_changed, complex_setting_changed, root_urlconf_changed, static_storage_changed, static_finders_changed, form_renderer_changed, auth_password_validators_changed, user_model_swapped, update_toolbar_config, reset_hashers, Options.setting_changed, update_level_tags, uninstall_if_needed, clear_caches, FileSystemStorage._clear_cached_properties, FileSystemStorage._clear_cached_properties, FileSystemStorage._clear_cached_properties, FileSystemStorage._clear_cached_properties, FileSystemStorage._clear_cached_properties, FileSystemStorage._clear_cached_properties, StaticFilesStorage._clear_cached_properties

Path	Location
.DS_Store	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/.DS_Store
grappelli/.DS_Store	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/.DS_Store
grappelli/js/grappelli.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/grappelli.js
grappelli/js/jquery.grp_related_m2m.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/jquery.grp_related_m2m.js
grappelli/js/jquery.grp_autocomplete_fk.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/jquery.grp_autocomplete_fk.js
grappelli/js/jquery.grp_autocomplete_generic.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/jquery.grp_autocomplete_generic.js
grappelli/js/jquery.grp_timepicker.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/jquery.grp_timepicker.js
grappelli/js/jquery.grp_collapsible_group.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/jquery.grp_collapsible_group.js
grappelli/js/jquery.grp_related_generic.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/jquery.grp_related_generic.js
grappelli/js/jquery.grp_related_fk.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/jquery.grp_related_fk.js
grappelli/js/jquery.grp_collapsible.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/jquery.grp_collapsible.js
grappelli/js/grappelli.min.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/grappelli.min.js
grappelli/js/jquery.grp_autocomplete_m2m.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/jquery.grp_autocomplete_m2m.js
grappelli/js/jquery.grp_inline.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/jquery.grp_inline.js
grappelli/images/spritesheet-1694777276.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/spritesheet-1694777276.png
grappelli/images/backgrounds/loading-small.gif	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/backgrounds/loading-small.gif
grappelli/images/backgrounds/changelist-results.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/backgrounds/changelist-results.png
grappelli/images/backgrounds/ui-sortable-placeholder.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/backgrounds/ui-sortable-placeholder.png
grappelli/images/backgrounds/nav-grabber.gif	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/backgrounds/nav-grabber.gif
grappelli/images/backgrounds/messagelist.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/backgrounds/messagelist.png
grappelli/images/icons/ui-datepicker-next.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/ui-datepicker-next.png
grappelli/images/icons/link-external-small_hover.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/link-external-small_hover.png
grappelli/images/icons/tools-arrow-up-handler_hover.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/tools-arrow-up-handler_hover.png
grappelli/images/icons/date-hierarchy-back.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/date-hierarchy-back.png
grappelli/images/icons/tools-delete-handler-predelete.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/tools-delete-handler-predelete.png
grappelli/images/icons/breadcrumbs-rtl.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/breadcrumbs-rtl.png
grappelli/images/icons/datepicker_hover.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/datepicker_hover.png
grappelli/images/icons/tools-trash-handler_hover.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/tools-trash-handler_hover.png
grappelli/images/icons/selector-add-m2m-vertical_hover.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/selector-add-m2m-vertical_hover.png
grappelli/images/icons/tools-related-remove-handler-small_hover.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/tools-related-remove-handler-small_hover.png
grappelli/images/icons/sorted-descending.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/sorted-descending.png
grappelli/images/icons/breadcrumbs_hover.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/breadcrumbs_hover.png
grappelli/images/icons/tools-viewsite-link_hover.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/tools-viewsite-link_hover.png
grappelli/images/icons/object-tools-add-link.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/object-tools-add-link.png
grappelli/images/icons/tools-related-edit-handler-small-disabled.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/tools-related-edit-handler-small-disabled.png
grappelli/images/icons/tools-related-remove-handler-small-disabled.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/tools-related-remove-handler-small-disabled.png
grappelli/images/icons/sorted-ascending.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/sorted-ascending.png
grappelli/images/icons/link-internal-rtl-small_hover.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/link-internal-rtl-small_hover.png
grappelli/images/icons/pulldown-handler_selected.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/pulldown-handler_selected.png
grappelli/images/icons/tools-delete-handler_hover.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/tools-delete-handler_hover.png

Content Detail

Versions

Time

Resource usage

Browser timing

Settings from app.settings

Headers

Request headers

Response headers

WSGI environ

Request

View information

No cookies

No session data

No GET data

No POST data

SQL queries from 1 connection

Static files (720 found, 2 used)

Static file paths

Static file apps

Static files

django.contrib.staticfiles.finders.AppDirectoriesFinder (720 files)

Templates (6 rendered)

Template path

Templates

Context processors

Cache calls from 1 backend

Summary

Commands

Signals